Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3. [1]

2007年10月20日 · Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with congestive heart failure.

Enoximone is an imidazolone derivative currently undergoing trials in patients with congestive heart failure refractory to conventional therapy. It is a phosphodiesterase inhibitor with both positive inotropic and vasodilator properties, and is active by both oral and intravenous routes of …

Enoximone is a phosphodiesterase type-3 inhibitor that exerts most effect on the myocardium; it has positive inotropic properties and vasodilator activity. Indications and dose For enoximone

2012年10月31日 · Enoximone is an imidazolone derivative currently undergoing trials in patients with congestive heart failure refractory to conventional therapy. It is a phosphodiesterase inhibitor with both positive inotropic and vasodilator properties, and is active by both oral and intravenous routes of administration.

Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with congestive heart failure.

The primary objective is a reduction in auto-positive end-expiratory pressure (PEEP) after enoximone compared to baseline. A dose-titration will test for dose dependency. Secondary objectives are a reduction in ventilator pressures, a reduction in pulmonary artery pressures and an increase in cardiac output.

Enoximone is an imidazole derivative with selective PDE III inhibition. It is useful for the short-term support of cardiac output in patients with chronic heart failure, in whom elevated catecholamine levels lead to the downregulation of β-receptors.

本品在肝、脾、肾及白血病细胞中逐渐代谢转化成阿糖胞苷，后者抑制DNA合成而显示抗肿瘤作用。 英文名称：Enoximone (MDL-17043,Fenoximone) 、 氢甲苯咪酮，甲硫咪唑酮，腈甲咪酮. 本品对接种L1210和人 淋巴性白血病 细胞的小鼠有延长生命的效果。 造血组织增生，1.5mg/kg以上见胸腺皮质 淋巴细胞 减少、SGOT、LDH上升。 大鼠和家兔在器官形成期静脉内给药，发现体重增加受抑、未成熟胎仔增加、胎仔骨髓异常、外形异常。 Ames试验 未见异常。 小鼠的 微核试 …

2007年2月1日 · 本药为选择性强效的磷酸二酯酶Ⅲ型抑制剂，有明显增加心肌收缩力和扩张血管作用，能增加心排出量、心脏指数、左室心搏做功指数、降低右房压、肺毛细血管契嵌压、平均肺动脉压及平均动脉压，心率增快，另有改善左心室舒张期顺应性的作用。 严重充血性心力衰竭:首剂0.5mg/kg静脉注射,每隔15min可再注射1次，每次递增0.5mg／kg，最大剂量3mg／kg。 心脏外科手术:最初静脉注射1mg/kg,之后每分钟3～10 μ g／kg，连续给药25～29小时。 1 ﹒心血管系 …